证券之星消息，8月27日医药商业板块较上一交易日下跌2.71%，塞力医疗领跌。当日上证指数报收于 3800.35，下跌1.76%。深证成指报收于12295.07，下跌1.43%。医药商业板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603716 | 塞力医疗 | 33.15 | -8.93% | 48.47万 | 16.71亿 | | 603122 | 合量中国 | 6.81 | -5.15% | 15.81万 | 1.10亿 | | 300937 | 药易购 | 28.63 | -5.10% | 3.49万 | 1.03亿 | | 600538 | 国发股份 | 6.29 | -4.98% | 24.72万 ﺎ | 1.60亿 | | 301017 | 漱玉平民 | 12.27 | -4.88% | 6.39万 | 8026.19万 | | 000078 | 海于生物 | 2.64 | -4.35% | 62.28万 | 1.68亿 | | 605266 | 健之佳 | ...

据证券之星公开数据整理，近期瑞康医药（002589）发布2025年中报。根据财报显示，瑞康医药净利润 同比下降32.35%。截至本报告期末，公司营业总收入35.44亿元，同比下降12.11%，归母净利润1816.64 万元，同比下降32.35%。按单季度数据看，第二季度营业总收入17.87亿元，同比下降11.23%，第二季 度归母净利润399.54万元，同比下降65.8%。 财报体检工具显示： 建议关注公司现金流状况（货币资金/流动负债仅为68.41%、近3年经营性现金流均值/流动负债仅为 2.92%） 证券之星价投圈财报分析工具显示： 业务评价：公司去年的ROIC为1.19%，资本回报率不强。去年的净利率为0.51%，算上全部成本后，公 司产品或服务的附加值不高。从历史年报数据统计来看，公司近10年来中位数ROIC为4.76%，中位投资 回报较弱，其中最惨年份2022年的ROIC为-11.98%，投资回报极差。公司历史上的财报非常一般，公司 上市来已有年报13份，亏损年份2次，显示生意模式比较脆弱。 偿债能力：公司现金资产非常健康。 商业模式：公司业绩主要依靠研发及营销驱动。需要仔细研究这类驱动力背后的实际 ...

瑞康医药集团股份有限公司 2025 年半年度财务报告 2025 年半年度财务报告 2025 年 8 月 1 | | | | 二、财务报表 3 | | --- | | 三、公司基本情况 20 | | 四、财务报表的编制基础 21 | | 五、重要会计政策及会计估计 21 | | 六、税项 45 | | 七、合并财务报表项目注释 46 | | 八、研发支出 94 | | 九、合并范围的变更 95 | | 十、在其他主体中的权益 98 | | 十一、政府补助 109 | | 十二、与金融工具相关的风险 110 | | 十三、公允价值的披露 112 | | 十四、关联方及关联交易 114 | | 十五、股份支付 118 | | 十六、承诺及或有事项 119 | | 十七、资产负债表日后事项 119 | | 十八、其他重要事项 120 | | 十九、母公司财务报表主要项目注释 121 | | 二十、补充资料 138 | | 二十一、财务报表之批准 139 | 瑞康医药集团股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的 ...

瑞康医药集团股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：瑞康医药集团股份有限公司 单位：万元 | 资金往来方名称 | 往来方与上 市公司的关 | 上市公司核 算的会计科 | 2025 年期初 往来资金余 | 2025 年半年 度往来累计 | 2025 年半 年度往来 | 2025 年半 年度偿还 | 2025 年半年 度末往来资 | 往来 形成 | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 联关系 | 目 | 额 | 发生金额 (不含利息) | 资金的利 息(如有) | 累计发生 金额 | 金余额 | 原因 | | | 烟台龙慧康母婴护理有 限公司 | 子公司 | 其他应收款 | 1,102.49 | 505.09 | | 502.67 | 1,104.91 | 借款 | 非经营性往来 | | 吉祥火(烟台)医药科技 有限公司 | 子公司 | 其他应收款 | 18,801.23 | 0.00 | | 0.00 | 18,801.23 | 借款 | 非经营性往来 | ...

瑞康医药集团股份有限公司 2025 年半年度报告全文 2025 年半年度报告 2025 年 8 月 1 瑞康医药集团股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人韩旭、主管会计工作负责人冯芸及会计机构负责人(会计主管 人员)曹庆岩声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 可能存在行业竞争、经营与管理、市场、国家政策等风险，敬请广大投 资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | 2 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 6 | | | 第三节 | 管理层讨论与分析 9 | | | 第四节 | 公司治理、环境和社会 | 22 | | 第五节 | 重要事项 | 27 | | 第六节 | 股份变动及股东情况 33 | | | 第七节 | 债券相关情 ...

中国经济网北京8月15日讯(记者郭文培)8月13日，瑞康医药（002589）集团股份有限公司(以下简称瑞康 医药)披露公告称，公司收到济南市济阳区监察委员会签发的《变更留置通知书》，济南市济阳区监察 委员会已解除对公司董事、董事会秘书及副总裁李喆的留置措施，变更为责令候查措施。 根据瑞康医药此前公告，李喆1986年出生，硕士学历。历任加拿大永明金融蒙特利尔分部理财顾问、加 拿大帝国商业银行多伦多分部基金管理专员、国金证券上海承销保荐分公司投行项目经理。 ...

Group 1 - Ruikang Pharmaceutical's executive Li Zhe has had his detention changed to a notice of investigation, indicating a shift in the investigation phase [1] - The change from detention to a notice of investigation suggests a reduced level of coercion, highlighting the importance of internal control and compliance systems in listed companies [1] Group 2 - Zhixiang Jintai has initiated a Phase III clinical trial for GR1802 injection for allergic rhinitis, following communication with the National Medical Products Administration [2] - GR1802 is slightly behind in clinical progress compared to two other approved drugs targeting the same indication, but successful commercialization could lead to competition with Dupilumab [2] Group 3 - Rongchang Biopharmaceutical's innovative drug RC18 (Taitaxip) for primary Sjögren's syndrome has met its primary endpoint in Phase III clinical trials, marking a potential first in the global market for this indication [3] - If approved, this drug could provide a breakthrough treatment for millions of patients in China and strengthen Rongchang's position in the autoimmune field [3] Group 4 - Hengrui Medicine's SHR-A2102, a targeted antibody-drug conjugate (ADC) for Nectin-4, has received approval for clinical trials in combination with Atezolizumab for recurrent/metastatic head and neck squamous cell carcinoma [4] - There is currently only one similar product on the market, Padcev, which is projected to generate $1.949 billion in sales in 2024, indicating significant market potential for this target [4] Group 5 - BeiGene has launched the first domestic Phase III clinical trial for subcutaneous Tislelizumab, a PD-1 inhibitor, for use in combination with chemotherapy for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [5] - The subcutaneous formulation is becoming a competitive area for PD-1/PD-L1 inhibitors, with three other subcutaneous PD-1/L1 products already approved globally [5]

Group 1: China Unicom - Company revenue exceeded RMB 200 billion in the first half of the year, with a total profit of RMB 17.7 billion, representing a year-on-year increase of 5.2% [1] - Internet communication revenue reached RMB 131.9 billion, while intelligent network revenue amounted to RMB 45.4 billion, accounting for 26% of total revenue [1] - The number of connected users surpassed 1.2 billion, with mobile and broadband users increasing by over 11 million, reaching a total of 480 million [1] Group 2: Kweichow Moutai - The net profit for the first half of the year increased by 8.89%, with favorable factors outweighing unfavorable ones [2] Group 3: Shuanghui Development - The company reported a total meat product export volume of 1.57 million tons, a year-on-year increase of 3.67%, and total revenue of RMB 28.5 billion, up 3.00% [4] - The total profit decreased by 2.36%, while the net profit attributable to shareholders rose by 1.17% due to improved profitability in tax-exempt businesses [4] Group 4: Pengding Holdings - The company achieved a revenue of RMB 16.375 billion, a year-on-year increase of 24.75%, and a net profit of RMB 1.233 billion, up 57.22% [6] - The increase in revenue was attributed to a rise in customer orders [6] Group 5: Jinlongyu - The company reported a net profit increase of 60.07%, with revenue reaching RMB 115.68 billion, up from RMB 109.48 billion [9] - The growth in revenue was driven by increased sales of kitchen foods, feed raw materials, and oil technology products [9] Group 6: Other Companies - Zhenray Technology reported a turnaround in net profit due to significant growth in main business revenue [12] - Zhongke Sanhuan achieved a net profit increase of 160.82%, despite a revenue decline of 11.17% [16]

Mergers and Acquisitions - Jin Chengzi plans to issue shares and pay cash to acquire 55% stake in Samit from eight parties including Wang Yongyang and Huang Meng, while also raising supporting funds [1] - Quzhou Development intends to purchase 95.46% of Xian Dao Electronic Technology Co., Ltd. through share issuance and will raise supporting funds [2] Performance Disclosure - Zhuyue Group reported a net profit of 585 million yuan for the first half of 2025, representing a year-on-year increase of 57.83%, with total revenue of 10.412 billion yuan, up 14.89% [3] - Zhenlei Technology announced a net profit of 62.32 million yuan for the first half of 2025, marking a significant year-on-year growth of 1006.99%, with revenue of 205 million yuan, up 73.64% [4] Shareholding Changes - Baichuan Co., Ltd. major shareholder Zheng Tiejiang plans to reduce his stake by up to 3%, equivalent to 17.83 million shares, from September 4 to December 3, 2025, due to personal financial needs [5] - Taiping Bird's shareholder Chen Hongchao intends to reduce his stake by no more than 3%, or 14.13 million shares, from August 19 to November 18, 2025, also for personal financial reasons [6] - Kanghua Biology's shareholder Chuanfa Selected No. 3 plans to reduce his stake by up to 3%, or 389,840 shares, within three months from the disclosure date [7] Risk Matters - *ST Huamei announced it failed to rectify fund occupation issues within the mandated period, leading to a suspension of its stock starting August 13, 2025, with potential delisting risks if not resolved within two months [8] - Ruikang Pharmaceutical reported that its director and board secretary Li Zhe had his detention lifted and changed to a warning measure, with normal business operations continuing [9]

Group 1 - The company, Ruikang Pharmaceutical (002589.SZ), announced that it received a notice from the Jinan Jiuyang District Supervisory Committee on August 12, 2025, regarding the change of detention measures for Li Zhe, which has been lifted and replaced with a directive for supervision [1] - The company's production and operational status is currently normal, and Li Zhe is able to perform his duties normally [1]